Genomic and transcriptomic plasticity in treatment-naïve ovarian cancer

Keyphrases

• Tumor Heterogeneity 100%
• Nave 100%
• Intratumor 100%
• Ovarian Cancer 100%
• Omentum 100%
• Genomic Breakpoints 100%
• Phenotypic Plasticity 100%
• Transcriptomic Plasticity 100%
• Inpatient Treatment 100%
• Genetic Modification 50%
• Cyclin-dependent Kinase Inhibitor 2A (CDKN2A) 50%
• TP53 mutation 50%
• Cancer Genes 50%
• Fusion Gene 50%
• Metastasis 50%
• Cancer Genome 50%
• Wnt Signaling 50%
• Therapy Resistance 50%
• Recurrent Disease 50%
• Integrin Signaling 50%
• Tumor Site 50%
• Hedgehog Signaling 50%
• Tumor Samples 50%
• Peritoneal Metastasis 50%
• Cancer Pathways 50%
• Ovarian Tumor 50%
• Gene Expression Changes 50%
• Epithelial Ovarian Cancer 50%
• Genome Rearrangement 50%
• Gene Expression Differences 50%
• Stage IIIC 50%
• Transcriptional Profiling 50%
• Peritoneum 50%
• Chemokine Signaling 50%
• Gene Expression Dynamics 50%
• Tumor Gene Expression 50%
• FANCD2 50%
• Kataegis 50%
• Changing Environmental Conditions 50%
• Topographic Mapping 50%
• Quantitative Gene Expression 50%
• Frame Fusion 50%
• Tumor Analysis 50%
• Coding mutation 50%
• Heterogeneous Treatment Effects 50%
• Treatment Regime 50%
• Personalized Treatment Strategies 50%
• Local mutation 50%
• Rearrangements Class 50%

Biochemistry, Genetics and Molecular Biology

• Transcriptomics 100%
• Genomics 100%
• Gene Expression 60%
• Oncogene 20%
• Tumor Gene 20%
• Gene Expression Profiling 20%
• Upregulation 20%
• Fusion Gene 20%
• Hedgehog Signaling Pathway 20%
• Chemokine 20%
• FANCD2 20%
• Integrin 20%
• Cyclin Dependent Kinase Inhibitor 2A 20%